<DOC>
	<DOCNO>NCT01230307</DOCNO>
	<brief_summary>The central objective proposal establish vitamin D supplementation heart failure patient low vitamin D level improve outcomes compare placebo . In addition investigator also evaluate role genetics regard vitamin D heart failure . The investigator evaluate currently novel approach identify patient low vitamin D treat low vitamin D level . The investigator able evaluate importance vitamin D supplementation patient role genetics define outcome .</brief_summary>
	<brief_title>Vitamin D Supplementation Treatment Heart Failure</brief_title>
	<detailed_description>Primary Objective To determine rapid vitamin D supplementation affect biomarkers submaximal exercise capacity systolic HF patient low vitamin D status . Working Hypothesis 1 : HF patient supplement vitamin D 6 month low measure inflammation extracellular-matrix remodeling compare placebo . Working Hypothesis 2 : HF patient supplement vitamin D 6 month longer 6-minute walk length compare placebo . Secondary Objectives To establish relationship CYP2R1 variant surrogate marker systolic HF patient . Working Hypothesis 3 : HF patient CYP2R1 G allele high measure inflammation extracellular-matrix remodeling compare AA subject . This relationship also see subject CYP2R1 TagSNP variant . Working Hypothesis 4 : HF patient CYP2R1 variant allele shorter 6-minute walk length compare subject without variant . To genotype HF subject VDR variant additional tag SNPs , ascertain relationship VDR genetic variation surrogate marker systolic HF patient . Working Hypothesis 5 : HF patient VDR variant great measure inflammation extracellular-matrix remodeling compare subject without VDR variant . Working Hypothesis 6 : HF patient VDR variant shorter 6-minute walk length compare subject without variant .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<mesh_term>Cholecalciferol</mesh_term>
	<criteria>HF patient LV systolic dysfunction ischemic nonischemic origin LVEF &lt; 40 % use nuclear ventriculography echocardiography within last 6 month . Attempts make optimize medical therapy participant stable medication least 3 month . Patients 25 ( OH ) D level 1025 ng/ml Inability give inform consent Patients sarcoidosis granulomatous disease alter vitamin D metabolism Patients primary valvular HF , hypertrophic cardiomyopathy , druginduced HF Renal dysfunction define serum creatinine &gt; 2.5 mg/dl Pregnant woman Patients &lt; 18 year age Patients vitamin D supplementation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Vitamin D</keyword>
	<keyword>Systolic failure</keyword>
	<keyword>Genomics</keyword>
	<keyword>Biomarkers</keyword>
	<keyword>Exercise</keyword>
	<keyword>Quality Life</keyword>
</DOC>